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During catalytic activation of the spliceosome, snRNP
remodeling events occur, leading to the formation of a
35S U5 snRNP that contains a large group of proteins,
including Prp19 and CDC5, not found in 20S U5 snRNPs.
To investigate the function of 35S U5 proteins, we immu-
noaffinity purified human spliceosomes that had not yet
undergone catalytic activation (designated BDU1), which
contained U2, U4, U5, and U6, but lacked U1 snRNA.
Comparison of the protein compositions of BDU1 and
activated B* spliceosomes revealed that, whereas U4/U6
snRNP proteins are stably associated with BDU1 spliceo-
somes, 35S U5-associated proteins (which are present in
B*) are largely absent, suggesting that they are dispensa-
ble for complex B formation. Indeed, immunodepletion/
complementation experiments demonstrated that a subset
of 35S U5 proteins including Prp19, which form a stable
heteromeric complex, are required prior to catalytic step 1
of splicing, but not for stable integration of U4/U6.U5
tri-snRNPs. Thus, comparison of the proteomes of spliceo-
somal complexes at defined stages can provide information
as to which proteins function as a group at a particular
step of splicing.
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Introduction
Pre-mRNA splicing is catalyzed by the spliceosome, a highly
dynamic RNP machine. The main components of the major
spliceosome are the U1, U2, U4, U5, and U6 snRNPs (Burge
et al, 1999). These RNA–protein complexes together with a
large number of non-snRNP splicing factors totaling well over
120 distinct proteins (Hartmuth et al, 2002; Jurica et al, 2002;
Makarov et al, 2002; Rappsilber et al, 2002; Zhou et al, 2002)
associate with the pre-mRNA in an ordered manner (Burge
et al, 1999). First, the U1 snRNP interacts with the 50 splice
site, followed by the stable association of U2 snRNP with the
branch site to form spliceosomal complex A. The pre-as-
sembled 25S U4/U6.U5 tri-snRNP is then recruited to form
complex B. The latter is structurally rearranged to form the
catalytically activated spliceosome, which subsequently cat-
alyzes the first transesterification reaction, generating
complex C. After the second step of splicing, the mRNA is
released, the post-spliceosomal complex disassembles, and
the snRNPs are recycled for new rounds of splicing. Thus,
spliceosome formation goes through many intermediate
stages, the most stable of which (e.g., A, B, and C complexes)
can be detected biochemically, for example, by native gel
electrophoresis. Many additional stable intermediates, such
as the recently purified activated spliceosome B*, also appear
to exist (Makarov et al, 2002; reviewed by Brow, 2002).
The most decisive step during the spliceosome maturation
process is the conversion of complex B, which does not
contain an active site, into the catalytically activated spliceo-
some B*, which is poised to catalyze both steps of splicing.
Activation of the spliceosome entails major structural
changes, including the displacement of U1 from the 50 splice
site, unwinding of the U4 and U6 base-pairing interaction,
and the subsequent base pairing of U6 with the 50 splice site
and the U2 snRNA (Nilsen, 1994; Staley and Guthrie, 1998).
These rearrangements result in the dissociation of the U1 and
U4 snRNPs during the activation step. The resulting RNA
network forms the core of the newly formed catalytic center
of the spliceosome.
While spliceosome activation is well characterized at the
RNA level, the role of proteins at this stage, as well as RNP
remodeling events accompanying activation, is only poorly
understood. Proteins of the DEAD/H-box family of RNA/RNP
unwindases appear to be one of the driving forces that
mediate RNA rearrangements at this step. For example,
Prp28/U5-100K has been implicated in displacing U1 from
the 50 splice site (Staley and Guthrie, 1999; Chen et al, 2001),
whereas Brr2/U5-200K appears to facilitate U4/U6 unwinding
(Laggerbauer et al, 1998; Raghunathan and Guthrie, 1998).
In yeast, evidence has been provided that Prp19p plays
an essential role in spliceosome activation (Tarn et al,
1993a, b). Prp19p is present in a heteromeric protein complex
that consists of at least eight proteins (the NTC, nineteen
complex) (Tarn et al, 1994; Tsai et al, 1999; Chen et al, 2002),
and more recent data suggest that it is part of a very large
RNP complex containing U2, U5, and U6 snRNA, as well as
many additional proteins (Ohi et al, 2002). The NTC complex
acts subsequent to U4 dissociation, stabilizing the association
of U5 and U6 with the activated spliceosome (Chan et al,
2003). In humans, hPrp19p co-purifies with CDC5 in a larger
complex containing approximately 30 proteins, and this
CDC5/Prp19 complex was reported to play a role in the
second step of splicing (Ajuh et al, 2000).
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We recently immunoaffinity purified the activated B*
spliceosome using antipeptide antibodies against the splicing
factor SKIP (Makarov et al, 2002). We intentionally purified
spliceosomal complexes under stringent conditions (i.e., in
the presence of heparin) so that only stably bound proteins
would be present. Consistent with the absence of U4, the
purified activated spliceosome lacked all U4/U6-associated
proteins. In addition, a group of 16 proteins (see Table I),
including CDC5, Prp19 and additional proteins that were
previously shown to be physically associated with Prp19
(Tarn et al, 1994; Tsai et al, 1999; Ben-Yehuda et al, 2000;
Chen et al, 2002; Ohi and Gould, 2002), were also stably
associated with the activated spliceosome, as well as a novel
35S form of the U5 snRNP (Makarov et al, 2002). These
results indicated that the U5 snRNP is remodeled during
activation, and that the 16 proteins that are stably associated
with it within the activated spliceosome may play a role in
activation or potentially at an earlier stage, for example
during tri-snRNP integration into the spliceosome.
To learn more about the driving forces behind spliceosome
activation, and in particular the contribution of 35S U5-
associated proteins to this process, we set out to isolate
spliceosomal complexes prior to activation but after stable
recruitment of the U4/U6.U5 tri-snRNP. Indeed, using anti-
bodies against the U4/U6-specific 61K protein, we affinity
purified spliceosomal B complexes that contain stably inte-
grated, intact U4/U6.U5 tri-snRNPs but lack U1 snRNPs
(henceforth denoted BDU1). The protein composition of
these complexes differed dramatically from that of the acti-
vated spliceosome; all U4/U6-specific proteins were present in
the BDU1 complexes, whereas essentially all 35S U5-specific
proteins were largely absent. We addressed a possible role of
35S U5-specific proteins in spliceosome activation by perform-
ing immunodepletion/complementation assays in splicing ac-
tive Hela nuclear extract, and demonstrate that a subset of
them, including CDC5 and Prp19, function after tri-snRNP
addition but prior to/during the first catalytic step of splicing.
Results
Purification of BDU1 spliceosomes
To isolate spliceosomes just prior to their activation, but after
stable integration of the U4/U6.U5 tri-snRNP, we used anti-
peptide antibodies against the U4/U6 protein 61K (hPrp31),
which had previously been shown to be required for forma-
tion of stable tri-snRNPs (Makarova et al, 2002). Splicing
complexes were allowed to form after incubation of pre-
mRNA (MINX) with splicing active HeLa nuclear extract.
After addition of heparin, immunoprecipitation was per-
formed with anti-61K antibodies at different time points.
Unspliced pre-mRNA was efficiently precipitated after
10 min (when B complex is efficiently formed) and also at
later time points, whereas no precipitation of splicing inter-
mediates or products was observed even at time points when
efficient splicing had occurred (not shown). Thus, there is a
window during spliceosome assembly (i.e., after tri-snRNP
addition but prior to activation) when the 61K protein, and
thus the U4/U6.U5 tri-snRNP as well (see below), is stably
associated with the spliceosome, such that it remains bound
even in the presence of heparin. Notably, under the same
stringent conditions, 25S U4/U6.U5 tri-snRNPs present in the
extract completely dissociate (not shown).
For biochemical analyses, we immunoaffinity purified
preparative amounts of spliceosomes formed after 10 min of
splicing. Bound spliceosomal complexes were then eluted
with antigenic 61K peptide and further purified by glycerol
gradient centrifugation. Purified spliceosomes contained stoi-
chiometric amounts of uncleaved pre-mRNA, U2, U4, U5, and
U6 snRNA but lacked U1 snRNA (Figure 1A, lane 1). Thus, in
contrast to the activated spliceosome, which was isolated
under identical conditions but with anti-SKIP antibodies
(Figure 1A, lane 2), spliceosomes purified with anti-61K
antibodies contain U4 snRNA. They, therefore, resemble com-
plex B, but differ from it in that they lack the U1 snRNP. We
therefore refer to these complexes as BDU1 spliceosomes.
To determine whether U4 is base paired with U6 in BDU1
spliceosomes, psoralen crosslinking studies were performed
with affinity-purified complexes that had been fractionated
on a glycerol gradient. Gradient fractions containing BDU1 or
B* complexes, or purified tri-snRNPs (which served as a
positive control for a U4/U6 crosslink), were UV irradiated
in the presence or absence of psoralen (AMT), and RNA–RNA
crosslinks were analyzed by Northern blotting, probing se-
quentially for U6 and U2 snRNA (Figure 1B). Multiple U6
snRNA-containing crosslinks were observed, one of which
(designated U4U6) was clearly present in BDU1 complexes
but only weakly detected in the activated spliceosome
(Figure 1B, compare lanes 5 and 7). This band was the
major crosslink obtained with purified U4/U6.U5 tri-
snRNPs (lane 9), demonstrating that it is a U4/U6 crosslink.
Thus, U4 and U6 are still base paired in BDU1 spliceosomes,
confirming that they have not undergone catalytic activation.
Two of the U6-containing bands were also detected with a
probe specific for the U2 snRNA (lanes 11 and 13), indicating
that they represent U2/U6 crosslinks. Based on their migra-
tion behavior, the major U2/U6 crosslinks observed in both
BDU1 and B* appear to correspond to the well-characterized
U2/U6 interaction between complementary regions of the 50
end of U2 and the 30 end of U6 snRNA (Hausner et al, 1990).
This so-called U2/U6 helix II base-pairing interaction does
not require U4/U6 unwinding. As previous crosslinking
studies analyzing spliceosomes were performed in the pre-
sence of nuclear extract and large amounts of a U2/U6 helix II
crosslink are observed in extracts even in the absence of
splicing (Hausner et al, 1990), it was previously not possible
to determine precisely at what stage of spliceosome assembly
this base-pairing interaction first occurs. Thus, our psoralen
crosslinking studies performed with purified spliceosomal
complexes suggest that U2/U6 helix II is formed at the time
of B complex formation.
A crosslink containing U6 that precisely co-migrated with a
pre-mRNA-containing crosslink (designated Pre-mRNAxU6)
was also observed (Figure 1B, compare lanes 1 and 5),
indicating that U6 contacts the pre-mRNA in BDU1 spliceo-
somes. The fact that this band was not observed after probing
for U2 (lane 11), and that the signals of the non-crosslinked
32P-labeled pre-mRNA are of equal intensity in both the U2
and U6 panels, confirms that the band designated Pre-
mRNAxU6 in lane 5 does not contain solely 32P-labeled pre-
mRNA. Although the crosslinking site has not been precisely
mapped, the presence of this crosslink in activated B*
spliceosomes (lanes 3 and 7) raises the possibility that it
may represent a base-pairing interaction between the region
of U6 snRNA containing the ACAGA box and the 50 end of the
Functional characterization of 35S U5 snRNP proteins
OV Makarova et al
The EMBO Journal VOL 23 | NO 12 | 2004 &2004 European Molecular Biology Organization2382
intron (for a summary of known RNA interactions in spliceo-
some, see Nilsen, 1994; Staley and Guthrie, 1998). We note
that a U6/50 splice site interaction can potentially occur
concomitantly with U4/U6 base pairing.
Consistent with their designation as B complexes, which
have been reported to sediment approximately as a 50S
particle (Frendewey and Keller, 1985), purified BDU1 spliceo-
somes sedimented as a 45S complex on glycerol gradients
(not shown). They also exhibited a migration behavior
similar to spliceosomal B complexes formed in vitro in Hela
nuclear extract, when analyzed by native gel electrophoresis
(Figure 1C, cf lane 6 with lanes 1–5). Note that, under the
conditions used for native gel electrophoresis (i.e., in the
presence of heparin), the U1 snRNP has been reported to
dissociate from the spliceosomal B complex (Konarska and
Sharp, 1986). By eluting this complex from the gel and
analyzing its snRNA composition, we have confirmed that
the spliceosomal complex designated B that we observe after
native gel electrophoresis of splicing reactions in fact repre-
sents a BDU1 spliceosome; it contains U2, U4, U5, and U6
snRNA, but U1 is clearly absent (not shown).
In the presence of nuclear extract in which endogenous
snRNPs had been destroyed by microccocal nuclease treat-
ment, the purified BDU1 complex catalyzed both steps of
splicing, whereas naked pre-mRNA did not (Figure 2). These
experiments demonstrate that the purified BDU1 spliceosome
does not require complementation with U4/U6.U5 tri-snRNPs
or U1 snRNPs for its activity, and that it is thus functionally
committed for subsequent activation and the catalytic steps
of splicing.
Figure 1 Characterization of immunoaffinity-purified BDU1 spliceosomes. (A) RNA composition of BDU1 versus activated B* spliceosomes.
RNAs extracted from gradient-purified BDU1 (lane 1), B* (lane 2) or total snRNPs (lane 3) were analyzed by denaturing PAGE and visualized by
silver staining. (B) Identification of RNA base-pairing interactions in BDU1. Gradient-fractionated BDU1 (lanes 1–2, 5–6, and 11–12), B* (lanes
3–4, 7–8, and 13–14), or U4/U6.U5 tri-snRNPs (lanes 9–10 and 15–16) were incubated in the absence (even lanes) or presence (odd lanes) of
psoralen (AMT) prior to UV irradiation. RNA was analyzed by denaturing PAGE, followed by either autoradiography to directly detect the 32P-
labeled pre-mRNA present in the BDU1 and B* spliceosomes (lanes 1–4), or by Northern blotting with 32P-labeled probes specific for U6
(lanes 5–10) or U2 (lanes 11–16). (C) Migration behavior of purified BDU1 spliceosomes on native agarose gels. 32P-labeled MINX
pre-mRNA was incubated under splicing conditions with HeLa nuclear extract for 0–30 min (lanes 1–5), and spliceosome assembly was
analyzed on a 2% agarose gel, together with immunoaffinity-purified BDU1 (lane 6). The positions of the H, A, and B complexes are indicated
on the left.
Figure 2 BDU1 spliceosomes catalyze splicing in the absence of
exogenously added snRNPs. Immunoaffinity-purified BDU1 spliceo-
somes (SPL) (lanes 1–7) or 32P-labeled MINX pre-mRNA (RNA)
(lanes 8–14) were incubated for 0–80 min (as indicated) under
splicing conditions in the presence of 20% micrococcal nuclease-
treated nuclear extract. RNAs were analyzed by denaturing PAGE
and visualized by autoradiography. The positions of the pre-mRNA,
and the splicing intermediates and products, are indicated on the
left.
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Protein composition of BDU1 versus activated
spliceosomes
To determine its protein composition, the purified BDU1
complex was fractionated by glycerol gradient centrifugation
and proteins isolated from the 45S peak fractions were
separated by SDS–PAGE and characterized by MALDI mass
spectrometry (MS). More than 70 proteins were identified and
are summarized in Table I. Thus, compared to the activated
B* spliceosome (Table I; Makarov et al, 2002), BDU1 contains
significantly fewer proteins. Consistent with the absence of
Table I Comparison of the proteome of the purified BDU1 spliceosome with that of the activated spliceosome (complex B*), the 35S U5 snRNP,
and the 25S U4/U6.U5 tri-snRNP particle
Proteins in the dark blue box, namely NPW38BP, NPW38, NCoR-1, hPrp4 kinase, FBP-21, TBLR-1, SMC1, and p220/NPAT, are not found in the
activated spliceosome. Most of the 35S U5 snRNP proteins highlighted red are either absent or significantly under-represented (indicated by
italics) in the BDU1 complex. The protein compositions of complex B*, the 35S U5 snRNP, and the tri-snRNP, as well as the color code for the
various groups of proteins, was taken from Makarov et al (2002). In this manuscript, the group of proteins highlighted red are referred to as 35S
U5 snRNP proteins. For accession numbers of proteins from complexes BDU1 and B*, the 35S U5 snRNP, and tri-snRNP, see Table S2 in
Supplementary data.
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U1 snRNA, no U1 snRNP-specific proteins (i.e., 70K, A and C)
were identified. Most U2 snRNP proteins, such as A0, B00, SF3a
and SF3b subunits, SPF30 and hPrp43 that were previously
found in isolated 17S U2 snRNPs and the purified complex A
(Hartmuth et al, 2002; Will et al, 2002), were present in the
BDU1 complex.
The protein compositions of the BDU1 and activated B*
spliceosome differ significantly with respect to the presence/
absence of two groups of proteins (Table I). First, BDU1
contains the U4/U6-specific proteins 90K, 61K, 60K, 15.5K,
and 20K (CypH), while these are essentially absent in the
activated B* complex (Table I). This finding, together with
the fact that U4 and U6 are still base-paired, as evidenced by
psoralen crosslinking (see above), strongly supports the idea
that an intact U4/U6 snRNP is present in the BDU1 spliceo-
some. Moreover, the U4/U6.U5 tri-snRNP also appears to be
essentially intact in BDU1. That is, the only U5 protein
missing is 100K (hPrp28). Furthermore, both the U4/U6-61K
and U5-102K proteins, which interact with each other and
mediate stable tri-snRNP formation (Makarova et al, 2002),
are present, suggesting that the two particles are still bridged
in BDU1.
The second major difference in protein composition be-
tween BDU1 and B* is that all of the 35S U5-specific proteins,
including Prp19 and CDC5 (highlighted red in Table I) that
are found in the activated spliceosome, are absent or under-
represented in BDU1 (i.e., the sequence coverage is two- to
three-fold lower compared to that of U2 or U5 proteins). To
perform a more accurate comparison, activated and BDU1
spliceosomes were immunoaffinity purified in parallel under
the same stringent conditions, and the amount of material
loaded onto the gel was normalized. LC-MSMS, focusing on
the U4/U6 snRNP proteins and 35S U5 proteins, was subse-
quently performed and confirmed that the 35S U5 proteins
are largely absent in the BDU1 complex; only hPrp19 and
SKIP were identified by two peptides each and CDC5 and
hSyf3 by one peptide (Supplementary Table S1). In contrast,
nearly all of the 35S U5 proteins, with the exception of hIsy1,
were clearly more abundant in the purified B* complex. For
example, eight peptides were obtained for hPrp19 and CDC5,
and 11 for SKIP. The difference in the abundance of the U4/U6
snRNP proteins between BDU1 and B* was similarly pro-
nounced but in the opposite way; that is, two to 11 peptides
were obtained for the U4/U6 proteins in the BDU1 spliceo-
some, while none were obtained from B* (Supplementary
Table S1). For comparison, the sequence coverage of U5
snRNP proteins, such as 220K, 200K, 116K, and 102K, was
very similar in both complexes, confirming that equal molar
amounts of both spliceosomes had been analyzed
(Supplementary Table S1).
To provide more quantitative information about the ab-
sence or presence of the 35S U5-associated proteins, as well
as U4/U6-specific proteins, we performed immunoblotting
experiments with selected antibodies (Figure 3). We normal-
ized the amount of each complex applied to the blot accord-
ing to the amount of 32P-labeled pre-mRNA. Indeed,
antibodies against the stably associated U5-116K and U5-
40K proteins confirmed that equal molar amounts of each
spliceosome were present (Figure 3). Subsequent immuno-
blotting experiments demonstrated that the U4/U6-specific
90K and 60K proteins, as well as the U2-associated protein
SPF30, are present in BDU1 but not in the activated spliceo-
some. Conversely, the 35S U5 proteins Prp19, CDC5L, Syf1,
Syf3, and SKIP were essentially absent from BDU1 but pre-
sent in the activated spliceosome. Thus, whereas the U4/U6
proteins are stably associated with the spliceosome prior to
activation, they dissociate or are destabilized at the time of
activation. In contrast, the 35S U5-associated group of pro-
teins become stably integrated into the spliceosome during
transition from the B complex to the activated spliceosome.
This observation suggests that the latter group of proteins
may play a major role in the activation of the spliceosome
rather than in the stable integration of the tri-snRNP.
However, it is also conceivable that, despite the fact that
they may only be loosely associated with the BDU1 spliceo-
some (and thus lost due to heparin treatment), one or more of
the 35S U5 snRNP proteins may play a role in tri-snRNP
integration and thus B complex formation.
Spliceosomal complex B forms in the absence of a
subset of 35S U5 proteins
To determine whether one or more of the 35S U5-specific
proteins play a role in tri-snRNP integration, we carried
out immunodepletion/complementation studies with HeLa
nuclear extract. For this purpose, we raised antibodies against
the 35S U5 protein CDC5. To define more precisely which
proteins are stably associated with CDC5 and thus potentially
co-immunodepleted, we first performed immunoaffinity
chromatography with nuclear extract and antipeptide anti-
bodies raised against CDC5. The bound complexes were
eluted with an excess of CDC5 peptide and the eluate
fractionated on a 5–20% glycerol gradient. Proteins were
isolated from fractions across the gradient and analyzed by
SDS–PAGE (Figure 4). A group of seven proteins co-migrated
in fractions 13–15, indicating that they form a complex that
Figure 3 Protein composition of BDU1 versus activated B* spliceo-
somes. BDU1 and B* spliceosomes were immunoaffinity purified
under identical conditions and subjected to glycerol gradient cen-
trifugation. Proteins from BDU1 or B* were separated by SDS–
PAGE, blotted onto a membrane and immunostained with affinity-
purified antibodies against selected proteins, as indicated on the
right.
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sediments with a Svedberg value of 14S. Proteins present in
the 14S peak were analyzed by MALDI-MS and identified as
CDC5, Hsp73, b-catenin-like 1, PRL1, Prp19, AD002, and
SPF27. MS analyses further revealed that the proteins
Npw38 and Npw38BP co-migrate at the top of the gradient,
suggesting that they were co-isolated with the CDC5/Prp19
complex but then dissociated from it during centrifugation.
With the exception of the b-catenin-like 1 protein, 14S
CDC5/Prp19 complex consists primarily of a subset of 35S U5
proteins (i.e., CDC5, Hsp73, PRL1, Prp19, AD002, and SPF27)
(Makarov et al, 2002). To determine whether this subset of
35S U5-associated proteins play a role in splicing, we im-
munodepleted nuclear extract of the CDC5/Prp19 complex
using anti-CDC5 and anti-AD002 antibodies. The level of each
protein was significantly reduced in their respective immu-
nodepleted extract when compared with the mock-depleted
extract, as evidenced by immunoblotting (Figure 5A).
Consistent with the fact that they are present together in a
stable complex, depletion of CDC5 also led to a reduction in
AD002 and vice versa (Figure 5A, lanes 2 and 3). In vitro
splicing was subsequently performed with mock-depleted
extract and extract depleted with both anti-CDC5 and anti-
AD002 antibodies. As shown in Figure 5B, splicing activity
was significantly reduced in the CDC5/AD002-depleted as
compared to mock-depleted extract (cf lanes 1–4 and 5–8).
Significantly, addition of immunoaffinity-purified 14S CDC5/
Prp19 complex (i.e., gradient fraction 14 from Figure 4)
partially restored splicing activity to the depleted extract
(lanes 8–12).
To determine at what step of the splicing reaction the 14S
CDC5/Prp19 complex first acts, we analyzed splicing com-
plex formation in mock- and CDC5/AD002-depleted extract
by agarose gel electrophoresis. Relative to the mock-depleted
extract (Figure 5C, lanes 1–4), no significant decrease in the
formation of A or B complex was observed with the CDC5/
AD002-depleted extract (Figure 5C, lanes 5–8). Due to the fact
that the catalytic steps of splicing occur very rapidly with the
MINX pre-mRNA, C complex is difficult to detect (Das and
Reed, 1999).
To determine whether or not the complex designated B that
we observe in the absence of the 14S CDC5/Prp19 complex
has undergone activation (i.e., release of U4), we performed
immunoprecipitation experiments under the same conditions
used to isolate BDU1 spliceosomes with anti-61K antibodies.
After allowing for splicing complex formation, spliceosomes
were immunoprecipitated from mock- or CDC5/AD002-de-
pleted extract and their RNA composition was analyzed by
30-end labeling with 32P-pCp, followed by denaturing PAGE.
The RNA compositions of spliceosomes immunoprecipitated
from mock- and CDC5/AD002-depleted extract were essen-
tially identical (Figure 5D); when antibodies were preblocked
with cognate peptide, essentially no RNA was precipitated
(not shown). Importantly, in addition to U2 and U5 (due to
inefficient end labeling, the U6 snRNA is difficult to detect), a
similar level of U4 snRNA was detected in both cases. These
results demonstrate that the majority of spliceosomes present
have not undergone activation and, thus, spliceosomal
complex B can form even in the absence of the CDC5/
Prp19 complex, but splicing is blocked prior to step 1 of
splicing.
Discussion
To gain insight into the multiple RNP rearrangements and
changes in protein composition of the spliceosome during its
maturation, catalytic activity, and subsequent disassembly,
we have set out to isolate various spliceosomal complexes
under identical stringent conditions at defined assembly/
functional stages. Using antipeptide antibodies directed
against spliceosomal proteins that are transiently stably
associated with the spliceosome, we have now been able to
isolate two spliceosomal complexes (BDU1 and the activated
spliceosome) under the same conditions, allowing a mean-
ingful comparison of their protein compositions via MS.
These results demonstrate that, in addition to the highly
stable spliceosomal complexes detected by standard bio-
chemical methods, there exist additional spliceosomal inter-
mediates that transiently form configurations of high
stability, and that such intermediates can be isolated by
targeting the suitable epitope for immunoaffinity selection.
This method can theoretically be extended to isolate addi-
tional spliceosomal complexes and thus generate additional
‘snapshots’ of the spliceosome’s changing protein composi-
tion and RNP structure.
Figure 4 Sedimentation behavior and protein composition of
CDC5/Prp19-containing complexes. Complexes were immunoaffi-
nity purified from HeLa nuclear extract with anti-CDC5 antibodies
and subjected to 5–20% glycerol gradient centrifugation. Proteins
from uneven fractions were separated by SDS–PAGE and stained
with Coomassie. The following proteins (indicated with arrows)
were identified by MS: CDC5 (NP_001244), HSP73 (NP_006588),
b-catenin-like 1 (NP_110517), PRL1 (NP_002660), Prp19 (NP_055317),
AD002 (AAF14858), SPF27 (NP_005863), Npw38 (NP_005701), and
Npw38BP (NP_057396).
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Composition of the BDU1 spliceosome
The protein composition of the BDU1 spliceosome differed
markedly from that of the activated B* spliceosome in that
U4/U6-associated proteins (which were not found in B*)
were present, but a group of 16 35S U5-associated proteins
that are stably associated with B* were largely absent. Only
minimal amounts of a subset of these proteins were detected
by MS or immunoblotting. That some proteins appear to be
present at a very low level in BDU1 could reflect the existence
of a subpopulation of spliceosomes in which the 61K protein
is still stably associated and several 35S U5 snRNP proteins
have also been stably integrated. BDU1 contained a group of
eight proteins, including Npw38, Npw38BP, N-CoR1, hPrp4
kinase, FBP-21, TBLR-1, SMC1, and p220(NPAT), not detected
in the pre-spliceosome or activated spliceosome (Table I)
(Hartmuth et al, 2002; Makarov et al, 2002). Thus, these
proteins could potentially function specifically at this stage of
spliceosome formation. Consistent with these proteins being
present in the BDU1 spliceosome, hPrp4 kinase was pre-
viously shown to interact with N-CoR (Dellaire et al, 2002).
Interestingly, the Saccharomyces pombe ortholog of hPrp4
kinase has been shown to be essential for splicing and to
phosphorylate the S. pombe prp1 protein (human U5-102K
protein) (Schwelnus et al, 2001). Thus, hPrp4 kinase, via
phosphorylation of the U5-102K protein, could play a role in
tri-snRNP rearrangement during spliceosome activation.
Interestingly, anti-61K affinity-purified spliceosomes
lacked the U1 snRNP. The absence of U1 may simply be
due to the presence of heparin during the isolation procedure,
and thus anti-61K affinity-purified spliceosomes likely repre-
sent spliceosomal complex B that has been depleted of U1.
Alternatively, the BDU1 spliceosome could represent a bona
fide spliceosome intermediate in which the U1 snRNP/50
splice site interaction has been actively disrupted, but the
U4/U6 base-pairing interaction remains intact. The detection
of a pre-mRNA/U6 snRNA crosslink (Figure 1B) is a first
indication that this may indeed be the case. However, more
detailed analyses are required to map the precise U6 cross-
linking site on the pre-mRNA. In this respect, it is interesting
to note that, in the minor U12-type spliceosome, interaction
of U6atac with the 50 splice site was observed prior to
complete unwinding of the U4atac/U6atac base-pairing inter-
action (Frilander and Steitz, 2001). Complementation experi-
ments with micrococcal nuclease-treated nuclear extract
demonstrated that BDU1 can be chased into a catalytically
active complex in the absence of snRNPs. Thus, the presence
of U1 is not required for the subsequent activation of the
spliceosome. Displacement of U1 from the 50 splice site is a
Figure 5 Spliceosomal B complex forms in the absence of the CDC5/PRP19 complex. (A) Nuclear extracts are efficiently immunodepleted of
CDC5 and AD002. Western blot of mock-depleted (lane 1), CDC5-depleted (lane 2) or AD002-depleted (lane 3) extract probed with anti-CDC5
(upper panel) or anti-AD002 (lower panel) antibodies. (B) Time course of splicing of [32P] MINX pre-mRNA in mock-depleted extract (MOCK,
lanes 1–4) or extract depleted with CDC5 and AD002 (DCDC5/DAD002, lanes 5–8), or CDC5/AD002-depleted extract complemented with
purified CDC5/PRP19 complex (fraction no. 14, from the gradient in Figure 4) (lanes 9–12). RNA was analyzed by denaturing PAGE and
visualized by autoradiography. The pre-mRNA, and splicing intermediates and products are indicated on the left. (C) The CDC5/PRP19
complex is not required for B-complex formation. Spliceosome assembly in mock-depleted extract, CDC5/AD002-depleted extract, or CDC5/
AD002-depleted extract complemented with the CDC5/PRP19 complex (lanes marked as in (B)) was analyzed at the indicated times by native
gel electrophoresis and visualized by autoradiography. The position of the H, A, and B complexes is indicated on the left. (D) Spliceosomes
formed in CDC5/AD002-depleted extract contain U4 snRNA. Spliceosomes were immunoprecipitated from mock- (lane 2) or CDC5/AD002-
depleted extract (lane 3) with anti-61K antibodies. RNA was isolated, end labeled with 32P-pCp, fractionated by denaturing PAGE, and
visualized by autoradiography. The identities of the RNAs are indicated on the right. Internally radiolabeled MINX pre-mRNA (lane 1) was
analyzed in parallel. Note that the band migrating at the position of U1 may also contain a pre-mRNA degradation product (*).
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prerequisite for the subsequent base-pairing interaction of the
U6 snRNA, and appears to be facilitated by the DEAD-box
protein hPrp28/U5-100K (Staley and Guthrie, 1999; Chen
et al, 2001). Intriguingly, hPrp28p/U5-100K is also no longer
stably associated with the BDU1 spliceosome, and thus may
dissociate together with U1 after catalyzing its displacement
from the 50 splice site.
Isolation of a well-defined, human 14S CDC5/Prp19
heteromeric complex
Using antibodies against CDC5, we isolated a heteromeric,
14S protein complex consisting of CDC5, Prp19, Hsp73,
b-catenin-like 1, PRL1, AD002, and SPF27. This CDC5/
Prp19 complex contains only a subset of the 35S U5 proteins
that are stably integrated first in the activated spliceosome.
Whether additional 35S U5 proteins associate and/or are
stably integrated into the spliceosome as a larger group,
together with the CDC5/Prp19 heptameric complex, is pre-
sently not clear. Previous studies characterizing the human
CDC5/Prp19 complex did not allow precise conclusions
regarding its protein composition (Ajuh et al, 2000). In the
latter studies, several CDC5-containing complexes were
isolated from HeLa nuclear extract either by immunoaffinity
chromatography or by size exclusion, followed by anion
exchange chromatography; in each case approximately 30
proteins appeared to co-purify with CDC5 (Table II). Only six
of these proteins, that is, CDC5, Prp19, PRL1, Hsp73
(CCAP1), SPF27, and CCAP6, were found in all preparations,
and thus were denoted core components of the CDC5-con-
taining complex (Ajuh et al, 2000; Table II). While five of
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aComplexes were immunoaffinity purified from HeLa nuclear extract with anti-CDC5 antibodies at 200 mM salt and further purified by glycerol
gradient centrifugation.
bComplexes were purified from HeLa nuclear extracts either by immunoaffinity chromatography with anti-CDC5 antibodies at 150 mM salt or
by tandem chromatographic steps involving gel filtration and ion exchange chromatography (Ajuh et al, 2000).
cComplexes were isolated from S. cerevisiae total cell extracts at 60 mM salt by tagging the Prp19 protein with an HA-tag and precipitating with
anti-HA antibodies (Tarn et al, 1994).
dComplexes were isolated from S. cerevisiae total cell extracts using the TAP method (150 mM salt) after tagging the Prp19 protein (Ohi et al,
2002).
eStably associated core protein in the CDC5 protein complex (Ajuh et al, 2000).
fSnt309 is a functional counterpart of S. pombe Cwf7 that is homologous to SPF27 (Ohi and Gould, 2002).
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these are also found in our 14S CDC5/Prp19 complex, CCAP6
is not. Furthermore, AD002, which is present in our complex,
was not previously reported to be a core component of CDC5
complex, although it co-purifies with CDC5 (AD002 is de-
noted CCAP2 by Ajuh et al, 2000).
The organization of the human 14S CDC5/Prp19 complex
differs considerably from the NTC complex in S. cerevisiae
(Table II). The latter complex has not been characterized in
its entirety; it consists of at least eight proteins with several
additional proteins also thought to be present (Chan et al,
2003). Of the known eight NTC components, only two, Prp19
and CDC5/Cef1, are found in our 14S CDC5/Prp19 complex.
A third candidate is Snt309, which may be a functional
counterpart of SPF27 (Ohi and Gould, 2002). That the NTC
complex likely consists of a much larger group of proteins is
further suggested by more recent studies (Ohi et al, 2002).
Using the TAP method, Prp19 in S. cerevisiae was shown to be
part of a large RNP complex containing numerous proteins
(Table II) as well as U2, U5, and U6 snRNAs. A comparison of
this complex with our 14S CDC5/Prp19 complex reveals that
their protein compositions are significantly different.
Interestingly, Npw38 and Npw38BP, which interact with
one another (Komuro et al, 1999), were reproducibly co-
isolated with the CDC5/Prp19 complex, but appeared to
dissociate during glycerol gradient centrifugation. Thus,
these proteins, which have no apparent orthologs in S.
cerevisiae (Supplementary Table S2), likely exhibit affinity
for one or more components of the CDC5/Prp19 complex,
and may play a role in recruiting this complex to the spliceo-
some, at least in higher eucaryotes. Indeed, Npw38 and
Npw38BP are stably associated with the BDU1 spliceosome
and could thus act as a docking site for the CDC5/Prp19
complex. Npw38 has been shown to interact with the U5-15K
(Dib1) protein (Zhang et al, 2000), and both of these proteins
together with Npw38BP are no longer stably associated with
the activated spliceosome (Table I), suggesting that they are
destabilized together during activation.
Function of the human CDC5/Prp19 complex
Previous functional analyses of the CDC5/Prp19 complex in
both yeast and humans were performed with a poorly
defined, large group of proteins (see above) (Ajuh et al,
2000; Chan et al, 2003). Thus, these studies do not allow
clear-cut conclusions as to precisely which components of the
CDC5/Prp19 complex are required for its function. We have
performed depletion/complementation studies with a well-
defined complex containing CDC5, Prp19, Hsp73, b-catenin-
like 1, PRL1, AD002, and SPF27, and thus can narrow down
the number of essential Prp19/CDC5 proteins to a very small
subset. The CDC5/Prp19 complex as defined here does not
play a role in tethering the tri-snRNP within the spliceosome,
as evidenced by the fact that this group of proteins is not
found in the BDU1 complex, where the tri-snRNP is stably
associated. Moreover, by physically depleting this complex,
we have further demonstrated that these proteins are not
required for the initial integration of the tri-snRNP. The 17S
U2-associated protein SPF30, which is present in the BDU1
spliceosome, likely plays an important role in recruiting/
tethering the U4/U6.U5 tri-snRNP complex; indeed SPF30
has been shown to interact with the U4/U6-90K protein
(Meister et al, 2001; Rappsilber et al, 2001). Interestingly,
SPF30 is no longer stably associated with the activated
spliceosome, consistent with the fact that the U4 snRNA
and the U4/U6-associated proteins (15.5K, 20K, 60K, 61K,
and 90K) dissociate or are destabilized at this time. This
finding underscores how comparison of the stable proteomes
of spliceosomal complexes at defined stages may help identi-
fy those proteins that are interaction partners and/or function
as a group at a particular step of the splicing process.
Depletion/complementation studies provided evidence
that the CDC5/Prp19 heptameric complex is required for
the first step of splicing. Thus, one or more members of
this complex initially function in a time window encompass-
ing the spliceosome activation step (i.e., after B-complex
formation but prior to step one of splicing). These results
differ from previous reports where immunodepletion of
human CDC5 and its associated proteins led predominantly
to a block in the second step of splicing (Ajuh et al, 2000).
One possible explanation for this difference is that a more
efficient depletion of the CDC5/Prp19 complex was achieved
in our hands due to the double depletion with both anti-CDC5
and anti-Ad002 antibodies. Although spliceosomal B complex
was observed in the absence of the CDC5/Prp19 complex, it
is presently not clear whether it functions prior to, during, or
after U4/U6 unwinding. A role in activation and/or the first
step of splicing, but not in tri-snRNP integration, likely also
holds for the nine other 35S U5 proteins that are present in
the activated spliceosome but were not present in the im-
munoaffinity-purified CDC5/Prp19 complex. Although direct
evidence that they function at this stage is lacking, the fact
that they are stably integrated into the spliceosome at the
same time as proteins of the CDC5/Prp19 complex is a first
indication that they may also function at a similar step.
Additional studies are clearly required to address this
question in more detail.
In yeast, the NTC complex acts subsequent to U4 dissocia-
tion, stabilizing the association of U5 and U6 with the
activated spliceosome (Chan et al, 2003). Recent studies in
yeast have also indicated that the U6-associated Lsm proteins
(Lsm2–8) are destabilized during activation of the spliceo-
some and that the NTC complex is required for their desta-
bilization (Chan et al, 2003). Our MS, as well as initial
immunoblotting data, suggests that Lsm proteins are not
destabilized during spliceosome activation in humans. That
is, several Lsm proteins were detected by MS both in BDU1
and activated B* spliceosomes, despite the fact that they are
generally difficult to detect by MS (Table I). In addition, in an
initial immunoblotting experiment with antibodies against
LSm4, we did not observe a decrease in signal between the
BDU1 and B*-activated spliceosome; in both complexes,
significant amounts of Lsm4 were detected (not shown).
However, additional experiments are required to clarify
whether the situation in humans indeed differs from that in
yeast.
The ability to isolate both BDU1 and activated spliceo-
somes under identical conditions allows us to address other
interesting questions. For example, what triggers U4 release
and other RNP rearrangements during spliceosome activa-
tion? Aside from RNA helicase activity, post-translational
modifications might also be a driving force that alters the
stability of protein–protein interactions within the spliceo-
some during its activation. To address this question, we have
begun to compare the modification states of proteins in the
BDU1 versus activated spliceosome.
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Materials and methods
In vitro splicing
HeLa nuclear extract was prepared according to Dignam et al
(1983). In vitro splicing, analytical immunoprecipitation of spliceo-
somes, and micrococcal nuclease (MN) digestions were performed
as described (Makarova et al, 2001, 2002). For analysis of splicing
complexes, heparin (5 mg/ml) was added to 5 ml of a splicing
reaction or 10 ml of immunoaffinity-purified BDU1 spliceosomes to a
final concentration of 1 mg/ml, and samples were placed on ice.
Complexes were analyzed on 2% agarose gels (Das and Reed,
1999).
Preparative immunoaffinity purification of spliceosomes and
MS
Antibodies raised against a peptide (aa 484–497) of U4/U6-61K or
the splicing factor SKIP (Makarov et al, 2002) were affinity purified
using a SulfoLink column (Pierce) containing the cognate peptide. A
4.0-ml splicing reaction containing 40% HeLa nuclear extract and
10–20 nM 32P-labeled MINX pre-mRNA (2000–4000 cpm/pmol) was
incubated at 301C for 10 min. Heparin was added to a final
concentration of 0.5 mg/ml and incubation at 301C continued for
5 min. Subsequent procedures were performed at 41C. The splicing
reaction was diluted 10-fold with IP buffer (20 mM HEPES, pH 7.9,
150 mM NaCl, 1.5 mM MgCl2, 0.5 mM DTT) containing 0.05% NP-
40 and incubated for 1 h with 1 ml of protein A–sepharose (PAS)
preblocked with 0.5 mg/ml of BSA and 50mg/ml of yeast tRNA. The
reaction was then incubated for 2 h with 1 ml of PAS charged with
affinity-purified anti-61K or anti-SKIP antibodies. Beads were
washed 6 with IP buffer containing 0.05% NP-40 and the bound
material was eluted by incubating for 1 h with 2.5 ml IP buffer
containing 5% glycerol, 0.05% NP-40, and 0.6 mg/ml of cognate
peptide. The eluate was loaded onto a 10–30% glycerol gradient
containing IP buffer and centrifuged in a TST41.14 rotor (Sorvall)
for 14 h at 31000 rpm. Gradients were fractionated into 24 0.5-ml
aliquots. Five fractions containing the peak of the BDU1 or B*
spliceosome were combined and complexes were pelletted by
centrifugation in a TH660 rotor (Sorvall) for 4 h at 60 000 rpm.
Pellets were resuspended in SDS–PAGE loading buffer, subjected to
10/13% SDS–PAGE, and stained with Coomassie. Individual bands
were excised from the gel and analyzed by both MALDI-MS and
LC-MSMS (Hartmuth et al, 2002). MS analyses of BDU1 were
performed twice: once alone and then subsequently in direct
comparison with an equal molar amount of B*.
Isolation of the CDC5/Prp19 complex
PAS beads (0.4 ml) were charged with affinity-purified antibodies
against a peptide of CDC5 (aa 106–124), preblocked with 0.5 mg/ml
of BSA and 50ml/ml of yeast tRNA, and incubated with 1 ml of HeLa
nuclear extract in C buffer (Dignam et al, 1983) for 2 h at 41C. Beads
were washed 6 with G200 buffer (20 mM HEPES, pH 7.9, 200 mM
NaCl, 1.5 mM MgCl2, 0.05% NP-40). The bound material was eluted
with 400ml of IP buffer containing 200 mM NaCl, 0.5 mg/ml
antigenic peptide, and 0.5 mM DTT, and loaded on a 5–20%
glycerol gradient containing IP buffer. Gradients were centrifuged
for 14.5 h at 35 000 rpm in a TH-660 rotor. 12S U1 and 20S U5
snRNPs served as S-value markers.
Psoralen crosslinking
A 1.25 ml splicing reaction containing 32P-labeled MINX pre-mRNA
was incubated for 10 min at 301C, heparin was added to a final
concentration of 0.5 mg/ml, and the reaction incubated for an
additional 5 min. The splicing reaction was diluted eight-fold with
IP buffer, precleaned by incubating with 300 ml PAS preblocked with
BSA and tRNA, and then incubated with 300ml PAS charged with
anti-61K antibodies (to isolate BDU1) or anti-SKIP antibodies (to
isolate activated B* spliceosomes). Complexes were eluted with
cognate peptide as described above and further purified by
centrifugation on a 10–30% glycerol gradient prepared with IP
buffer. Peak fractions from each gradient were combined and split
into two aliquots. Psoralen (AMT) was added to one aliquot to a
final concentration of 25mg/ml and incubated on ice for 10 min.
Both the psoralen-treated and nontreated aliquots were subse-
quently irradiated for 15 min at 365 nm on ice. After proteinase K
digestion, RNA was recovered by phenol–chloroform extraction and
ethanol precipitation, and separated on a 5% polyacrylamide, 7 M
urea gel (Hausner et al, 1990). The 32P-labeled pre-mRNA was
detected directly by autoradiography, whereas the U2 and U6
snRNAs were visualized by Northern blotting (Hartmuth et al,
2002). Psoralen crosslinking was performed in parallel with anti-
m3G affinity-purified, gradient-fractionated U4/U6.U5 tri-snRNPs
(Laggerbauer et al, 1998).
Immunoblotting
Proteins from BDU1 or B* spliceosomes were separated by SDS–
PAGE, transferred to Hybond P membrane and immunostained
with affinity-purified antibodies, using an ECL detection kit
(Amersham). Antibodies were raised in rabbits against the
following antigens: U5-116K (aa 1–117), U5-40K (full length); U4/
U6-90K (aa 287–302); U4/U6-60K (aa 58–94), Prp19 (aa 176–191),
CDC5 (aa 106–124), hSyf1 (aa 6–21), hSyf3 (aa 47–60), SKIP (aa
516–531), and KIAA0560 (aa 1470–1485).
Immunodepletion/complementation assays
HeLa nuclear extract (0.5 ml) in C buffer was incubated 2 with
75ml of PAS beads charged with affinity-purified antibodies against
CDC5 or a peptide of AD002 (aa 71–86) for 2 h at 41C with HOT
rotation. For double depletion, incubation with anti-CDC5 beads
was followed by anti-AD002 beads. The extract was then dialyzed
for 4 h against D buffer (Dignam et al, 1983) in a Slide-A-Lyzer 3.5K
(Pierce). Mock-depleted extracts were treated in an identical
manner, except that antibody was omitted. For complementation,
prior to dialysis, 100 ml of depleted extract was mixed with 56ml of
gradient fraction no. 14 (Figure 4) containing the CDC5/Prp19
complex at a concentration of B0.1 mg/ml, and then dialyzed as
above. Splicing reactions (10–20ml) contained 35% mock-, de-
pleted- or CDC/Prp19-complemented extract and 10 nM MINX
32P-labeled pre-mRNA (10 000–50 000 cpm/pmol).
Analysis of spliceosomal complexes formed
in CDC5/AD002-depleted extract
A 150 ml splicing reaction containing mock- or CDC5/AD002-
depleted extract and 10 nM MINX pre-mRNA was incubated at
301C for 10 min and subsequently treated with heparin as described
above. The reaction was diluted eight-fold with IP buffer containing
0.05% NP-40, incubated for 2 h at 41C with 30ml PAS charged with
anti-61K antibodies, and washed 6 with IP buffer containing
0.05% NP-40. RNA was isolated from the immunoprecipitated
spliceosomal complexes, 30-endlabeled with [32P]pCp, analyzed on
a 14% polyacrylamide/7 M urea gel, and visualized by autoradio-
graphy.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
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